Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease

Table 6

Patients with and without improvement of platelet count at EOT.

Variables	Patients with improvement in platelet count ()	Patients without improvement in platelet count ()	value
Age (year)			≤0.225
Male/female (, %)	39 (53%)/34 (47%)	17 (63%)/10 (37%)	≤0.394
Stage of hepatic fibrosis: (, %)
Mild to moderate fibrosis (F0, F1, and F2)	22 (30%)	1 (4%)	≤0.006
Advanced fibrosis and cirrhosis (F3 and F4)	51 (70%)	26 (96%)
PV diameter (mm)			≤0.009
Spleen size (cm)			≤0.001
Baseline total bilirubin (mg/dL)			≤0.028
Baseline albumin (g/dL)			≤0.013
Baseline ALT (IU/L)			≤0.284
Baseline AST (IU/L)			≤0.666
Type of treatment: (, %)
Dual	24 (33%)	5 (18.5)	≤0.160
Triple	49 (67%)	22 (81.5%)

PV: portal vein; ALT: alanine aminotransferase; AST: aspartate aminotransferase.